Novel Antibiotic Treatment of Gliosarcoma Reduces Tumor Size and Increases Survival
Abstract (Set) The present invention is directed to methods of using a bacteriostatic antibiotic to treat glioma and other brain tumors including astrocytoma, oligodendroglioma, glioblastoma multiform but also other cancer types including breast cancer, cervical cancer, AIDS related cancer, gastric cancer, head and neck cancer, prostate cancer and else. In particular, the bacteriostatic antibiotic or a pharmaceutically-acceptable salt thereof, is administered to a subject for a time and in an amount to treat, ameliorate or delay onset of symptoms associated with tumor growth in a subject having cancer. A delay in progression of disease in glioma patients can be measured by clinical manifestations. Treatment can stabilize, inhibit or delay the growth of a glioma tumor. In another aspect of the invention, the glioma treatments of the invention can include use of a second therapeutic agent. Such agents can be co-administered either as a single unit dosage form or as separate unit dosage forms. Such co-administration need not actually be identical in time but rather is intended to cover any use of the antibiotic agent in conjunction with a second therapeutic agent as part of a single treatment regimen. Accordingly, the invention provides a method of treating glioma by administering the bacteriostatic antibiotic, or a pharmaceutically-acceptable salt thereof, and one or more second therapeutic agent, or a pharmaceutically-acceptable salt thereof, to a subject for a time and in an amount to treat, ameliorate or delay onset or progression of symptoms associated with brain tumor in a subject having glioma or suspected of having glioma. Description (Set) Malignant gliomas are the most common type of primary brain tumors affecting about 16,000 new patients every year in the United States. The prognosis of these patients remains poor despite standard treatment with radiotherapy and temozolomide. The complexity of glioma cell biology challenges the development of molecular targeted therapy, which nevertheless holds the promise of providing new and more effective treatment options with less toxicity. JHU scientists have discovered that a known bacteriostatic antibiotic is a neuroprotective agent. Preliminary studies showed efficacy of the antibiotic agent in an in vivo gliosarcoma tumor model. JHU scientists have shown that treatment with the antibiotic agent significantly reduces tumor size and increases survival in gliosarcoma tumor models. JHU scientists determined that the beneficial effects are dosage dependent.• Treatment with the antibiotic agent stabilizes or inhibits glioma growth to increase patient quality of life and improve disease prognosis.
• Can be administered in combination with other cancer therapeutics to attack tumor cells on a multiple fronts in order to improve patient prognosis and survival.
• Use of known antibiotic reduces need for extensive compound screens and development time to speed clinical use. Proposed Use (Set) This technology can be commercialized as a stand-alone therapy for brain cancers or in combination with standard cancer therapies. The agent could be delivered using a wafer delivery system with or without combination treatment.
Inventor(s): Sattler, Rita ,Chipkin, Richard,Rothstein, Jeffrey D
Type of Offer: Licensing
« More Medical Patents